Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
Personalis commercially launched Real-Time Variant Tracker, optional supplemental results within its NeXT Personal MRD test that track resistance and therapeutically targetable variants as cancer biology evolves. The feature identifies clinically significant variants tied to FDA-approved therapies and NCCN guidelines, and moved from an Early Access Program begun in January 2026 to full commercial availability on October 20, 2026.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.